Karyopharm Therapeutics | KPTI - 债务



金融业
股票价格
USD
资产
USD 131.42M
现金及等价物
USD 90.85M
销售成本
USD 1.35M
流动资产
USD 126.33M
流动负债
USD 117.3M
债务
USD 299.23M
股息收益率
0
EBIT
USD -26.76M
EBITDA
USD -26.2M
员工
325
EPS每股收益
USD -1.02
股本和储备
USD -265.65M
销售毛利
USD 33.72M
债务利息支出
USD 12.55M
利息收入
USD -0.15
贷款资金
USD 264.49M
市值
USD 198.5M
净收入
USD -22.39M
营业费用
USD 61.83M
营业利润
USD -26.76M
普通股股本
USD 22.54M
税前利润
USD -22.39M
销售收入
USD 35.07M
销售和管理费用
USD 10.42M
股票
USD 4.04M
贸易债权人
USD 4.28M
应收帐款人
USD 23.36M


债务 更改 日
AbbVie USD 72.86B 5.36B 2026-03
Abbott USD 34.05B 20.19B 2026-03
Amgen USD 57.32B 2.72B 2026-03
AstraZeneca USD 32.24B 1.68B 2026-06
BioCryst Pharmaceuticals USD 828.6M 510K 2024-12
Bristol-Myers Squibb USD 46.43B 711M 2026-03
Eli Lilly USD 43.37B 867M 2026-03
Enanta Pharmaceuticals USD 1.35M 0 2024-12
GlaxoSmithKline GBP 19.06B 1.34B 2026-03
Incyte USD 38.27M 1.16M 2026-06
J&J USD 54.99B 7.05B 2026-03
Karyopharm Therapeutics USD 299.23M 35.14M 2025-12
MacroGenics USD 36.51M 500K 2026-03
Merck USD 49.12B 222M 2026-03
Nektar Therapeutics USD 0 0 2022-06
Novartis USD 49.01B 2.02B 2026-06
Novartis USD 47B 14.98B 2026-03
Pfizer USD 63.19B 536M 2026-06
Regeneron Pharmaceuticals USD 2.71B 400K 2026-06
Roche Holding CHF 33.03B 1.41B 2025-06
Sangamo BioSciences USD 0 0 2022-06
Takeda JPY 4.94T 58.13B 2026-06
Tectonic Therapeutic USD 876K 115K 2024-12
TG Therapeutics USD 754.44M 884K 2026-06
Ultragenyx Pharmaceutical USD 36M 2.17M 2025-12
Xencor USD 175.16M 12.58M 2026-03